Active substance
Gemfibrozil
- SFDA 1
- US FDA 22
- Health Canada 1
- US price lines 1
- NHS prices 2
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| LOPID | 600 mg | Film-coated tablet · Oral use | 30 Blister | SAR 49.35 | NCE · Prescription | Pfizer Pharma GmbH | Valid |
Indications — CHI Daman Drug Formulary
DYSLIPIDEMIA
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| LOPID | 600MG | tablet · oral | PFIZER PHARMS | Prescription | 21 Dec 1981 |
| GEMFIBROZIL | 600MG | tablet · oral | CHARTWELL MOLECULES | Prescription | 27 Sep 1993 |
| GEMFIBROZIL | 600MG | tablet · oral | INVAGEN PHARMS | Prescription | 27 Jul 2006 |
| GEMFIBROZIL | 600MG | tablet · oral | EPIC PHARMA LLC | Prescription | 26 Mar 2007 |
| GEMFIBROZIL | 600MG | tablet · oral | IMPAX PHARMS | Prescription | 1 Jun 2007 |
| GEMFIBROZIL | 600MG | tablet · oral | NORTHSTAR HLTHCARE | Prescription | 13 Sep 2010 |
| GEMFIBROZIL | 600MG | tablet · oral | AUROBINDO PHARMA LTD | Prescription | 16 Sep 2015 |
| GEMFIBROZIL | 600MG | tablet · oral | CADILA PHARMS LTD | Prescription | 17 Jun 2016 |
| GEMFIBROZIL | 600MG | tablet · oral | ASCENT PHARMS INC | Prescription | 13 Jan 2021 |
| LOPID | 200MG; 300MG | capsule · oral | PFIZER PHARMS | Discontinued | 21 Dec 1981 |
| GEMFIBROZIL | 300MG | capsule · oral | NATCO | Discontinued | 25 Jan 1993 |
| GEMFIBROZIL | 600MG | tablet · oral | TEVA | Discontinued | 31 Oct 1993 |
| GEMFIBROZIL | 600MG | tablet · oral | PHARMOBEDIENT | Discontinued | 16 Feb 1995 |
| GEMFIBROZIL | 600MG | tablet · oral | WATSON LABS | Discontinued | 28 Apr 1995 |
| GEMFIBROZIL | 600MG | tablet · oral | CHARTWELL RX | Discontinued | 29 Sep 1995 |
| GEMFIBROZIL | 600MG | tablet · oral | APOTEX | Discontinued | 20 Jul 1998 |
| GEMFIBROZIL | 600MG | tablet · oral | SUN PHARM INDS INC | Discontinued | 29 Dec 2008 |
| GEMFIBROZIL | 600MG | tablet · oral | HIKMA PHARMS | Discontinued | 16 Aug 2010 |
| GEMFIBROZIL | 600MG | tablet · oral | CADILA | Discontinued | 28 Aug 2018 |
| GEMFIBROZIL | 300MG | capsule · oral | PUREPAC PHARM | Discontinued | |
| GEMFIBROZIL | 600MG | tablet · oral | WATSON LABS | Discontinued | |
| GEMFIBROZIL | 600MG | tablet · oral | PUREPAC PHARM | Discontinued |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| TEVA-GEMFIBROZIL | 02142074 | 600 MG | TABLET · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | GEMFIBROZIL 600 MG TABLET | $0.10376 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Gemfibrozil 300mg capsules | £31.76 | 100 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Gemfibrozil 600mg tablets | £35.57 | 56 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 10 Dec 2020 LOPID — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Drug Interactions
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.